Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gneiss

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 9, 2004
Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosisR Ehling, A Lutterotti, J Wanschitz, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 9, 2004
Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativityC Gneiss, M Reindl, A Lutterotti, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 5, 2011
Olfactory threshold is impaired in early, active multiple sclerosisA Lutterotti, M Vedovello, M Reindl, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 26, 2009
High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot studyA Millonig, D Rudzki, M Hölzl, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 7, 2008
Comparative study of four different assays for the detection of binding antibodies against interferon-betaC Gneiss, M Brugger, A Millonig, et al.
European Journal of Neurology|June 14, 2008
MxA protein--an interferon beta biomarker in primary progressive multiple sclerosis patientsA Millonig, A Dressel, D Bahner, et al.
Journal of Neuroimmunology|March 25, 2006
Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodiesC Gneiss, P Tripp, R Ehling, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 18, 2008
Smoking is a risk factor for early conversion to clinically definite multiple sclerosisF Di Pauli, M Reindl, R Ehling, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 1, 2007
Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patientsC Gneiss, P Tripp, F Reichartseder, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 9, 2004
Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosisR Ehling, A Lutterotti, J Wanschitz, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 9, 2004
Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativityC Gneiss, M Reindl, A Lutterotti, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 5, 2011
Olfactory threshold is impaired in early, active multiple sclerosisA Lutterotti, M Vedovello, M Reindl, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 26, 2009
High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot studyA Millonig, D Rudzki, M Hölzl, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 7, 2008
Comparative study of four different assays for the detection of binding antibodies against interferon-betaC Gneiss, M Brugger, A Millonig, et al.
European Journal of Neurology|June 14, 2008
MxA protein--an interferon beta biomarker in primary progressive multiple sclerosis patientsA Millonig, A Dressel, D Bahner, et al.
Journal of Neuroimmunology|March 25, 2006
Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodiesC Gneiss, P Tripp, R Ehling, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 18, 2008
Smoking is a risk factor for early conversion to clinically definite multiple sclerosisF Di Pauli, M Reindl, R Ehling, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 1, 2007
Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patientsC Gneiss, P Tripp, F Reichartseder, et al.
Pageof 1